Griffiths Richard W, Elkord Eyad, Gilham David E, Ramani Vijay, Clarke Noel, Stern Peter L, Hawkins Robert E
Department of Medical Oncology, Christie Research Centre, Paterson Institute for Cancer Research, Manchester, UK.
Cancer Immunol Immunother. 2007 Nov;56(11):1743-53. doi: 10.1007/s00262-007-0318-z. Epub 2007 May 9.
Regulatory T cells are important in maintaining immune homeostasis, mediating peripheral tolerance and preventing autoimmunity. Increased frequencies of CD4(+)CD25(high )T regulatory (T(Reg)) cells have been documented in the peripheral blood of patients with several types of cancer consistent with a role in tumour escape from immunological control. We have investigated the presence of T(Reg) cells systemically and in situ in previously untreated patients with renal cell carcinoma (RCC).
We have shown that there is a significant increased frequency of CD4(+)CD25(high) T cells in RCC patients (n = 49) compared to normal donors (n = 38), respectively, 2.47% versus 1.50%; P < 0.0001. We confirmed these data using the FOXP3 marker of T(Reg) cells in a subset of these patients and normal donors. The population of T(Reg) cells identified showed the expected phenotype with CD4(+)CD25(high) population in both RCC patients and normal donors contained higher proportions of CD45RO and GITR than CD4(+)CD25(-/low) populations and exhibiting suppressive activity in an anti-CD3 and anti-CD28 induced proliferation assay. CD4(+)FOXP3(+) T cells were detected in the tumour microenvironment by immunofluorescence and the numbers enumerated in lymphocytes recovered following enzymatic disaggregations of biopsies; their frequency was higher in the tumour than the peripheral blood of the same patients. The early follow up data show an association between higher peripheral blood regulatory T-cell count and adverse overall survival.
These data confirm the increase of T(Reg) cells in RCC patients and provide impetus to further investigate modulation of T(Reg) activity in RCC patients as part of therapy.
调节性T细胞在维持免疫稳态、介导外周耐受和预防自身免疫方面起着重要作用。在几种类型癌症患者的外周血中,已发现CD4(+)CD25(高)调节性T(T(Reg))细胞频率增加,这与肿瘤逃避免疫控制的作用一致。我们研究了肾细胞癌(RCC)初治患者体内及原位T(Reg)细胞的存在情况。
我们发现,与正常供者(n = 38)相比,RCC患者(n = 49)中CD4(+)CD25(高) T细胞频率显著增加,分别为2.47%和1.50%;P < 0.0001。我们在这些患者和正常供者的一个亚组中使用T(Reg)细胞的FOXP3标志物证实了这些数据。所鉴定的T(Reg)细胞群体显示出预期的表型,RCC患者和正常供者中的CD4(+)CD25(高)群体比CD4(+)CD25(-/低)群体含有更高比例的CD45RO和糖皮质激素诱导的肿瘤坏死因子受体(GITR),并在抗CD3和抗CD28诱导的增殖试验中表现出抑制活性。通过免疫荧光在肿瘤微环境中检测到CD4(+)FOXP3(+) T细胞,并对活检组织酶解后回收的淋巴细胞进行计数;同一患者肿瘤中的频率高于外周血。早期随访数据显示外周血调节性T细胞计数较高与不良总生存之间存在关联。
这些数据证实了RCC患者中T(Reg)细胞增加,并为进一步研究作为治疗一部分调节RCC患者T(Reg)活性提供了动力。